UK firm teams up with Incepta on intranasal Covid vaccine
British biomedical firm ViraCorp has joined forces with leading Bangladeshi pharmaceutical company Incepta to develop needle-free Covid-19 vaccine, which uses state-of-the-art intra-nasal technology.
Under its subsidiary ViraVac, ViraCorp's new vaccine is based on the work of Lancaster virologist Dr Muhammad Munir, who has taken on the role of chief scientific officer at ViraCorp, says a press release.
The vaccine features a unique formulation and delivery method which means it not only protects against Covid-19, but it can be delivered by nasal spray and transported using traditional cold transportation, the release says.
This has numerous advantages compared to other vaccines currently on the market.
"Having a vaccine which can be transported easily and administered through a nasal delivery system reduces the heavy infrastructure and training requirements of a vaccination drive and will help ensure the vaccine can reach some of the world's most remote communities," said Dr Munir.
"This collaboration will be a milestone to provide a new delivery system making it a very attractive solution for vaccination in developing countries like ours, alongside remote communities," said Dr Abdul Muktadir, chairman and managing director of Incepta Vaccine Ltd.
Jon Chadwick, chief executive officer of ViraCorp, said, "By combining our resources, we will ensure the highest standard of quality in our work to make vaccines more available, both logistically and financially."
ViraCorp and its subsidiaries are aiming to lead a campaign against viral infections and diseases, while also providing humanitarian aid to the people and places that need it most.
Incepta Vaccine Ltd was established in 2011 with the primary objective to provide high quality vaccines to the vast majority of the population in Bangladesh and across the globe at an affordable price.
Incepta's facility has a yearly production capacity of 180 million single doses, or one billion doses in multi-dose format.
Comments